Leigh Schmidt
Family · Rolling Hills Estates, CANPI 1083248579
Payments from drug & device makers
Across 350 payments — averaging $48.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$8K
- AbbVie$2K
- Phadia US Inc.$2K
- AstraZeneca$1K
- Sanofi$1K
- Regeneron Healthcare Solutions, Inc.$468
- plus $3K from 33 others
Across 2 payments — averaging $375.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi$750
What the payments were for
- Consulting fees$5,95035%
- Speaking & faculty fees$1,2507%
- Travel & lodging$1,3828%
- Food & beverage$8,27749%
- Education$1091%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 21 | $7,530 |
| AbbVie | 100 | $2,167 |
| Phadia US Inc. | 6 | $1,509 |
| AstraZeneca | 26 | $1,102 |
| Sanofi | 30 | $1,058 |
| Regeneron Healthcare Solutions, Inc. | 20 | $468 |
| Pfizer | 28 | $437 |
| Corium, LLC | 16 | $274 |
| GSK | 10 | $239 |
| Lilly USA, LLC | 10 | $214 |
| Blueprint Medicines Corporation | 1 | $184 |
| Organon | 2 | $172 |
| Novo Nordisk | 8 | $163 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $158 |
| Amgen(2 entities) | 6 | $126 |
| Kaleo, Inc. | 5 | $96 |
| Genentech USA, Inc. | 3 | $86 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $82 |
| Bayer | 5 | $73 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $72 |
| Dermavant Sciences, Inc. | 2 | $69 |
| Sanofi Pasteur Inc. | 4 | $63 |
| Incyte Corporation | 3 | $63 |
| Alk-abello, Inc | 1 | $55 |
| Teva Pharmaceuticals USA, Inc. | 3 | $51 |
| Sage Therapeutics, LLC | 2 | $46 |
| LEO Pharma Inc. | 2 | $43 |
| Optinose US, Inc. | 1 | $42 |
| Merck | 2 | $41 |
| Regeneron | 1 | $40 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $39 |
| Amarin Pharma, Inc. | 2 | $37 |
| Bausch Health US, LLC | 2 | $36 |
| Almatica Pharma LLC | 2 | $30 |
| Exact Sciences | 1 | $26 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Lundbeck LLC | 1 | $20 |
| Cranial Technologies, Inc | 1 | $17 |
| Supernus Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,968 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TezspireTezepelumab-Ekko | 13 | $54,428 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $12,300 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 24 | $734 |
| Ipratropium Bromide | 22 | $539 |
| Metoprolol Succinate | 23 | $349 |
| Levothyroxine Sodium | 28 | $338 |
| Rosuvastatin Calcium | 23 | $331 |
| Atorvastatin Calcium | 27 | $300 |
| Losartan Potassium | 34 | $250 |
| Amlodipine Besylate | 30 | $208 |
| Hydrochlorothiazide | 12 | $148 |
| Lisinopril | 16 | $146 |
| Gabapentin | 11 | $140 |
| Trazodone Hcl | 14 | $72 |
| Alprazolam | 12 | $47 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTezspire, Breztri Aerosphere | $1,102 | $66,72827 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.
Other family in Rolling Hills Estates
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Nancy GardettoSan Diego$394K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Jenine StoneEscondido$231K
- Erin DwyerSan Diego$189K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.